Company Analysis
Sign in

YD Bio Limited (YDES)

Nasdaq: YDES · Services-Medical Laboratories · Irving, TX · filing with the SEC since 2024
Full chart Alerts Compare
Grade5.6
◀ Past 7.6● Present 3.6▶ Future 6.3
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$596,817+16.9%
Net income-$8.3M-488.8%
Earnings per share$-0.12-500.0%
Operating cash flow-$6.6M-439.5%
Cash$6.0M+91.8%
Debt$6764.00
Shareholders’ equity-$2.9M-143.3%
Shares, diluted66.7M+3.1%
Return on equityn/a
The recordfrom its filings
Filings in 202634
Newest filingOct 6 · 4
Annual reportApr 30, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$100,000
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Oct 6, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 6, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 10, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 8, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 1, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
Aug 11, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
Jul 1, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton YDES · research, not advice